Ocular and Systemic Results of Intravitreal Bevacizumab Injection in Retinopathy of Prematurity Treatment.
Bevacizumab
Denver II
neurodevelopment
retinopathy of prematurity
safety
Journal
Beyoglu eye journal
ISSN: 2587-0394
Titre abrégé: Beyoglu Eye J
Pays: Turkey
ID NLM: 101777848
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
05
2019
accepted:
07
03
2020
entrez:
31
1
2022
pubmed:
29
7
2020
medline:
29
7
2020
Statut:
epublish
Résumé
The aim of this study was to evaluate the effectiveness and safety of an intravitreal bevacizumab injection (IVB) in the treatment of retinopathy of prematurity (ROP). The medical records of patients who had received IVB treatment for ROP between January 2014 and October 2018. Anatomical and functional outcomes were evaluated. The Denver II Developmental Screening Test was administered and fluorescein angiography (FA) was performed in some cases. Thirty-eight eyes of 19 infants were included in the study. An IVB injection was administered to 9 infants with aggressive posterior ROP (APROP) disease (Group 1), 6 infants with any stage ROP with plus disease in zone I (Group 2), and 4 infants with stage 2-3 ROP with plus disease in zone II (Group 3). Complete retinal vascularization was observed in 24 eyes of 12 infants who received a single dose of bevacizumab without any additional treatment. Recurrence of the disease was observed in 12 eyes of 6 infants diagnosed with APROP and laser photocoagulation was performed. FA was performed to 5 IVB patients whose parents approved the procedure. The Denver II Developmental Screening Test was administered to all of the participants, and the test outcomes were consistent with the corrected age of the children, though 2 infants demonstrated a developmental delay in gross motor development tasks. Overall, good anatomical and functional results were obtained. IVB is an effective and relatively safe treatment modality for infants with ROP; however, prospective studies are required to provide more detailed information about systemic side effects.
Identifiants
pubmed: 35098067
doi: 10.14744/bej.2020.46855
pii: BEJ-5-73
pmc: PMC8784485
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73-80Informations de copyright
Copyright: © 2020 by Beyoglu Eye Training and Research Hospital.
Déclaration de conflit d'intérêts
Conflict of Interest: None declared.
Références
Retina. 2013 Feb;33(2):329-38
pubmed: 23099498
Arch Dis Child Fetal Neonatal Ed. 2013 Jul;98(4):F327-33
pubmed: 23269586
BMC Ophthalmol. 2015 Mar 08;15:20
pubmed: 25886603
Ophthalmology. 2011 Jan;118(1):176-83
pubmed: 20673589
Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):1023-34
pubmed: 21051703
Am J Ophthalmol. 2012 Feb;153(2):327-333.e1
pubmed: 21930258
J AAPOS. 2010 Feb;14(1):6-10
pubmed: 20227614
Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50
pubmed: 15747762
Res Dev Disabil. 2016 Jan;48:231-41
pubmed: 26630614
Neonatology. 2007;91(4):291-7
pubmed: 17575472
Ophthalmology. 2018 Dec;125(12):1961-1966
pubmed: 29887334
Pediatrics. 2016 Apr;137(4):
pubmed: 27244705
Retina. 2006 Sep;26(7 Suppl):S11-5
pubmed: 16946670
Arch Ophthalmol. 2005 Mar;123(3):406-7; discussion 409-10
pubmed: 15767491
Ophthalmology. 2014 Nov;121(11):2212-9
pubmed: 25001158
N Engl J Med. 2011 Feb 17;364(7):603-15
pubmed: 21323540
J Ophthalmol. 2014;2014:257286
pubmed: 25614828
Arch Ophthalmol. 2012 Aug;130(8):1000-6
pubmed: 22491394
Retina. 2017 Jan;37(1):97-111
pubmed: 27454223
Arch Ophthalmol. 1988 Apr;106(4):471-9
pubmed: 2895630
Graefes Arch Clin Exp Ophthalmol. 2015 Oct;253(10):1677-83
pubmed: 25501298
Arch Ophthalmol. 2005 Jul;123(7):991-9
pubmed: 16009843
Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3
pubmed: 18320201
Br J Ophthalmol. 2018 Feb;102(2):260-264
pubmed: 28655731
Cir Cir. 2017 Nov - Dec;85(6):478-484
pubmed: 28110900
J Pediatr Ophthalmol Strabismus. 2020 Jan 1;57(1):54-60
pubmed: 31972042
Retina. 2008 Jun;28(6):831-8
pubmed: 18536599
Retina. 2004 Aug;24(4):507-11
pubmed: 15300070
Br J Ophthalmol. 2014 Apr;98(4):507-12
pubmed: 24403566
Reprod Health. 2013;10 Suppl 1:S1
pubmed: 24625113